Fusafungine: Difference between revisions
No edit summary |
No edit summary |
||
Line 43: | Line 43: | ||
| synonyms = Fusafungin | | synonyms = Fusafungin | ||
}} | }} | ||
'''Fusafungine''' ([[International Nonproprietary Name|INN]]), also known as '''fusafungin''', is an active agent used in [[antibiotic]]s for treatment of [[nasal infection|nasal]] and [[throat infection]]. It also possesses [[anti-inflammatory]] properties. Fusafungine is a mixture of [[enniatin]] [[depsipeptide|cyclohexadepsipeptides]] made up of alternating <small>D</small>-α-hydroxyvaleric acid and <small>L</small>-''N''-methylamino acid residues,<ref>{{cite journal | journal = [[Biochemical Pharmacology]] | volume =50 |issue=12 22 |year=1995 |pages= 2105–2107 | title=Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins | author = Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud| doi = 10.1016/0006-2952(95)02045-4 | pmid=8849339}}</ref> produced by the [[Ascomycota|ascomycete]] '' | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Fusafungine''' ([[International Nonproprietary Name|INN]]), also known as '''fusafungin''', is an active agent used in [[antibiotic]]s for treatment of [[nasal infection|nasal]] and [[throat infection]]. It also possesses [[anti-inflammatory]] properties. Fusafungine is a mixture of [[enniatin]] [[depsipeptide|cyclohexadepsipeptides]] made up of alternating <small>D</small>-α-hydroxyvaleric acid and <small>L</small>-''N''-methylamino acid residues,<ref>{{cite journal | journal = [[Biochemical Pharmacology]] | volume =50 |issue=12 22 |year=1995 |pages= 2105–2107 | title=Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins | author = Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud| doi = 10.1016/0006-2952(95)02045-4 | pmid=8849339}}</ref> produced by the [[Ascomycota|ascomycete]] ''Fusarium lateritium'', and marketed by [[Servier]] under the trade names '''Locabiotal''', '''Bioparox''', and '''Locabiosol'''. | |||
According to a pooled analysis study done in the UK for the efficacy of fusafungine in [[Rhinopharyngitis|rhinopharingitis]], it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.<ref>{{cite pmid|15626253}}</ref> | According to a pooled analysis study done in the UK for the efficacy of fusafungine in [[Rhinopharyngitis|rhinopharingitis]], it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.<ref>{{cite pmid|15626253}}</ref> | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Throat preparations}} | {{Throat preparations}} | ||
[[Category:Antimicrobial peptides]] | [[Category:Antimicrobial peptides]] | ||
[[Category: | [[Category:Drug]] | ||
Latest revision as of 16:34, 13 April 2015
Clinical data | |
---|---|
Synonyms | Fusafungin |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C29H51N2O8 |
Molar mass | 555.72 g/mol[1] |
|
WikiDoc Resources for Fusafungine |
Articles |
---|
Most recent articles on Fusafungine Most cited articles on Fusafungine |
Media |
Powerpoint slides on Fusafungine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Fusafungine at Clinical Trials.gov Clinical Trials on Fusafungine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Fusafungine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Fusafungine Discussion groups on Fusafungine Patient Handouts on Fusafungine Directions to Hospitals Treating Fusafungine Risk calculators and risk factors for Fusafungine
|
Healthcare Provider Resources |
Causes & Risk Factors for Fusafungine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,[2] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharingitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.[3]
References
- ↑ Fusafungine at MeSH
- ↑ Daniel Levy, Aline Bluzat, Michel Seigneuret and Jean-Louis Rigaud (1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins". Biochemical Pharmacology. 50 (12 22): 2105–2107. doi:10.1016/0006-2952(95)02045-4. PMID 8849339.
- ↑ PMID 15626253 (PMID 15626253)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with incomplete PMID references
- Template:drugs.com link with non-standard subpage
- Articles with changed DrugBank identifier
- Articles with changed KEGG identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Antimicrobial peptides
- Drug